COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:

Key Record Dates Identifier: NCT01729754
Brief Title: A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) (reSURFACE 2)

First Submitted : November 13, 2012
First Submitted that Met QC Criteria : November 14, 2012
First Posted : November 20, 2012 (Estimate)

Results First Submitted : April 10, 2018
Results First Submitted that Met QC Criteria : May 25, 2018
Results First Posted : June 27, 2018

Last Update Submitted that Met QC Criteria : August 17, 2020
Last Update Posted : August 31, 2020